264 related articles for article (PubMed ID: 33579848)
1. Brain Metabolism and Microglia Activation in Mild Cognitive Impairment: A Combined [18F]FDG and [11C]-(R)-PK11195 PET Study.
Tondo G; Boccalini C; Caminiti SP; Presotto L; Filippi M; Magnani G; Frisoni GB; Iannaccone S; Perani D
J Alzheimers Dis; 2021; 80(1):433-445. PubMed ID: 33579848
[TBL] [Abstract][Full Text] [Related]
2. Influence of microglial activation on neuronal function in Alzheimer's and Parkinson's disease dementia.
Fan Z; Aman Y; Ahmed I; Chetelat G; Landeau B; Ray Chaudhuri K; Brooks DJ; Edison P
Alzheimers Dement; 2015 Jun; 11(6):608-21.e7. PubMed ID: 25239737
[TBL] [Abstract][Full Text] [Related]
3. The combined effects of microglia activation and brain glucose hypometabolism in early-onset Alzheimer's disease.
Tondo G; Iaccarino L; Caminiti SP; Presotto L; Santangelo R; Iannaccone S; Magnani G; Perani D
Alzheimers Res Ther; 2020 Apr; 12(1):50. PubMed ID: 32354345
[TBL] [Abstract][Full Text] [Related]
4. Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia.
Cerami C; Della Rosa PA; Magnani G; Santangelo R; Marcone A; Cappa SF; Perani D
Neuroimage Clin; 2015; 7():187-94. PubMed ID: 25610780
[TBL] [Abstract][Full Text] [Related]
5. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
[TBL] [Abstract][Full Text] [Related]
6. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
[TBL] [Abstract][Full Text] [Related]
7. Regional fluorodeoxyglucose metabolism and instrumental activities of daily living across the Alzheimer's disease spectrum.
Roy K; Pepin LC; Philiossaint M; Lorius N; Becker JA; Locascio JJ; Rentz DM; Sperling RA; Johnson KA; Marshall GA
J Alzheimers Dis; 2014; 42(1):291-300. PubMed ID: 24898635
[TBL] [Abstract][Full Text] [Related]
8. 18F-FDG PET diagnostic and prognostic patterns do not overlap in Alzheimer's disease (AD) patients at the mild cognitive impairment (MCI) stage.
Morbelli S; Bauckneht M; Arnaldi D; Picco A; Pardini M; Brugnolo A; Buschiazzo A; Pagani M; Girtler N; Nieri A; Chincarini A; De Carli F; Sambuceti G; Nobili F
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2073-2083. PubMed ID: 28785843
[TBL] [Abstract][Full Text] [Related]
9. Optimization of Statistical Single Subject Analysis of Brain FDG PET for the Prognosis of Mild Cognitive Impairment-to-Alzheimer's Disease Conversion.
Lange C; Suppa P; Frings L; Brenner W; Spies L; Buchert R
J Alzheimers Dis; 2016; 49(4):945-959. PubMed ID: 26577523
[TBL] [Abstract][Full Text] [Related]
10. Utility of Molecular and Structural Brain Imaging to Predict Progression from Mild Cognitive Impairment to Dementia.
Lan MJ; Ogden RT; Kumar D; Stern Y; Parsey RV; Pelton GH; Rubin-Falcone H; Pradhaban G; Zanderigo F; Miller JM; Mann JJ; Devanand DP
J Alzheimers Dis; 2017; 60(3):939-947. PubMed ID: 28984586
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic role of 11C-Pittsburgh compound B retention patterns and glucose metabolism by fluorine-18-fluorodeoxyglucose PET/CT in amnestic and nonamnestic mild cognitive impairment patients.
Jiménez-Bonilla JF; Banzo I; De Arcocha-Torres M; Quirce R; Martínez-Rodríguez I; Lavado-Pérez C; Bravo-Ferrer Z; Rodríguez-Rodríguez E; Sánchez-Juan P; Carril JM
Nucl Med Commun; 2016 Nov; 37(11):1189-96. PubMed ID: 27341411
[TBL] [Abstract][Full Text] [Related]
12. Regional Disconnection in Alzheimer Dementia and Amyloid-Positive Mild Cognitive Impairment: Association Between EEG Functional Connectivity and Brain Glucose Metabolism.
Smailovic U; Koenig T; Savitcheva I; Chiotis K; Nordberg A; Blennow K; Winblad B; Jelic V
Brain Connect; 2020 Dec; 10(10):555-565. PubMed ID: 33073602
[No Abstract] [Full Text] [Related]
13. Alteration patterns of brain glucose metabolism: comparisons of healthy controls, subjective memory impairment and mild cognitive impairment.
Song IU; Choi EK; Oh JK; Chung YA; Chung SW
Acta Radiol; 2016 Jan; 57(1):90-7. PubMed ID: 25538106
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of 18F-FDG-PET/MRI brain in dementia: Preliminary experience from a geriatric clinic in South India.
Mukku SSR; Sivakumar PT; Nagaraj C; Mangalore S; Harbishettar V; Varghese M
Asian J Psychiatr; 2019 Aug; 44():99-105. PubMed ID: 31336358
[TBL] [Abstract][Full Text] [Related]
15. Brain glucose metabolism in Lewy body dementia: implications for diagnostic criteria.
Caminiti SP; Sala A; Iaccarino L; Beretta L; Pilotto A; Gianolli L; Iannaccone S; Magnani G; Padovani A; Ferini-Strambi L; Perani D
Alzheimers Res Ther; 2019 Feb; 11(1):20. PubMed ID: 30797240
[TBL] [Abstract][Full Text] [Related]
16. Low plasma neurofilament light levels associated with raised cortical microglial activation suggest inflammation acts to protect prodromal Alzheimer's disease.
Parbo P; Madsen LS; Ismail R; Zetterberg H; Blennow K; Eskildsen SF; Vorup-Jensen T; Brooks DJ
Alzheimers Res Ther; 2020 Jan; 12(1):3. PubMed ID: 31898549
[TBL] [Abstract][Full Text] [Related]
17. Comparing fludeoxyglucose F18-PET assessment of regional cerebral glucose metabolism and [11C]dihydrotetrabenazine-PET in evaluation of early dementia and mild cognitive impairment.
Albin RL; Koeppe RA; Burke JF; Giordani B; Kilbourn MR; Gilman S; Frey KA
Arch Neurol; 2010 Apr; 67(4):440-6. PubMed ID: 20385910
[TBL] [Abstract][Full Text] [Related]
18. A Comparison of Two Statistical Mapping Tools for Automated Brain FDG-PET Analysis in Predicting Conversion to Alzheimer's Disease in Subjects with Mild Cognitive Impairment.
Garibotto V; Trombella S; Antelmi L; Bosco P; Redolfi A; Tabouret-Viaud C; Rager O; Gold G; Giannakopoulos P; Morbelli S; Nobili F; Perneczky R; Didic M; Guedj E; Drzezga A; Ossenkoppele R; Berckel BV; Ratib O; Frisoni GB
Curr Alzheimer Res; 2020; 17(13):1186-1194. PubMed ID: 33583380
[TBL] [Abstract][Full Text] [Related]
19. Brain metabolism and cerebrospinal fluid biomarkers profile of non-amnestic mild cognitive impairment in comparison to amnestic mild cognitive impairment and normal older subjects.
Coutinho AM; Porto FH; Duran FL; Prando S; Ono CR; Feitosa EA; Spíndola L; de Oliveira MO; do Vale PH; Gomes HR; Nitrini R; Brucki SM; Buchpiguel CA
Alzheimers Res Ther; 2015 Sep; 7(1):58. PubMed ID: 26373380
[TBL] [Abstract][Full Text] [Related]
20. Significance of visual hallucinations and cerebral hypometabolism in the risk of dementia in Parkinson's disease patients with mild cognitive impairment.
Gasca-Salas C; Clavero P; García-García D; Obeso JA; Rodríguez-Oroz MC
Hum Brain Mapp; 2016 Mar; 37(3):968-77. PubMed ID: 26663702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
